Although details have not been finalized, IIDA INDUSTRY CO., LTD., a manufacturer of foamed plastics used as antivibration and shock absorber materials, plans to build a production facility somewhere in suburban Detroit in 1999. Before then, the Aichi prefecture-headquartered company will open a sales office to launch marketing activities and to gather information. Iida Industry hopes to gain business from MITSUBISHI MOTORS CORP., TOYOTA MOTOR CORP. and other North American automotive transplant operations as well as from the Big Three U.S. car and truck builders. It is projecting sales in 2000 at $1.5 million.
Pharmaceutical manufacturers have available a new facility in Summit, New Jersey for pilot product production and pilot testing. Built and operated by the Hosokawa Micron Powder Systems part of HOSOKAWA MICRON CORP., the Hosokawa Pharma Tech Center meets current industry and Food and Drug Administration standards. The $1.1 million facility includes two processing suites designed to afford maximum Good Manufacturing Practices conditions, a clean equipment storage area, equipment washroom, material quarantine and release areas and a separate analytical laboratory with complete testing capabilities for all test runs. Hosokawa Micron Powder Systems, also located in Summit, is a supplier of integrated powder and particle processing systems.
Anticipating the launch of a treatment for diabetes around 2001, TAKEDA CHEMICAL INDUSTRIES, LTD. set up a marketing firm in New York City through its recently established U.S. holding company (see Japan-U.S. Business Report No. 340, January 1998, p. 2). Actos, which is undergoing Phase III clinical testing, will be comarketed by TAKEDA PHARMACEUTICALS AMERICA, INC. and ELI LILLY AND CO.
TAISHO PHARMACEUTICAL CO., LTD. has opened an office in New York City to organize and oversee clinical trials by a local contract research organization of NE- 100, a treatment for multiple personality disorders. Testing will begin in the spring of 1999.
An exchange rate of ¥135=$1.00 was used in this report.